Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine Tumors

Publisher： Karger

E-ISSN： 1423-0194|95|3|232-247

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.95, Iss.3, 2011-12, pp. : 232-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 47-50

Karger

Access to resources Recommend Favorite

Does Somatostatin or Gastric Inhibitory Peptide Receptor Expression Correlate with Tumor Grade and Stage in Gut Neuroendocrine Tumors?

By  

Neuroendocrinology, Vol. 101, Iss. 1, 2015-01 ,pp. : 45-57

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

By  

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 220-226

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide

By  

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 184-189

Karger

Access to resources Recommend Favorite

Differential Inhibition of Growth Hormone Secretion by Analogs Selective for Somatostatin Receptor Subtypes 2 and 5 in Human Growth-Hormone-Secreting Adenoma Cells in vitro

By  

Neuroendocrinology, Vol. 73, Iss. 5, 2001-05 ,pp. : 344-351

Karger

Access to resources Recommend Favorite